Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model

References

• Hegde U, Filie A, Little RF, . High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement:the role of flow cytometry versus cytology. Blood 2005;105:496–502.
   PubMed Web of Science ®Google Scholar
• Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2005;19:597–609, v.
   PubMed Web of Science ®Google Scholar
• Herman TS, Hammond N, Jones SE, . Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer 1979;43:390–397.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Bibeau F, El Weshi A, . Primary breast lymphoma: a report of 20 cases. Br J Haematol 2001;115:253–256.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Habermann TM, Colgan JP, . Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154–161.
   PubMed Web of Science ®Google Scholar
• Bos GM, van Putten WL, van der Holt B, . For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998;9:191–194.
   PubMed Web of Science ®Google Scholar
• Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990;8:141–145.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, . Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046–1052.
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, . Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129–133.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Zhang MJ. Cox proportional hazards regression models for survival data in cancer research. Cancer Treat Res 2002;113:59–70.
   PubMedGoogle Scholar
• Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001;2:85–97.
   PubMedGoogle Scholar
• Beyersmann J, Schumacher M. Time-dependent covariates in the proportional subdistribution hazards model for competing risks. Biostatistics 2008;9:765–776.
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Partial residuals for proportional hazards regression model. Biometrika 1982;69:239–241.
   Web of Science ®Google Scholar
• Yamamoto K, Taji H, Kagami Y, . LEED therapy followed by auto PBSCT for aggressive and relapsed malignant lymphoma. Rinsho Ketueki 2006;9:1022.
   Google Scholar
• Ogura M, Kagami Y, Taji H, . Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 2003;77:503–511.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, . ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, . Incidence and risk factors of central nervous system recurrence in aggressive lymphoma— a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149–157.
   PubMed Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Nome O, . Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, . Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol 2000;11:685–690.
   PubMed Web of Science ®Google Scholar
• van Besien K, Ha CS, Murphy S, . Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178–1184.
   PubMed Web of Science ®Google Scholar
• Jehan Z, Siraj AK, Abubaker J, . Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. Oncology 2008;75:71–80.
   PubMed Web of Science ®Google Scholar
• Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110:3102–3111.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, . Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516--the Southwest Oncology Group. J Clin Oncol 2009;27:114–119.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, . CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
   PubMed Web of Science ®Google Scholar
• Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009;89:577–583.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, . Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25: 4730–4735.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, . Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–468.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Hellmann M, Barnes J, . Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116:4283–4290.
   PubMed Web of Science ®Google Scholar
• Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006;20:319–332.
   PubMed Web of Science ®Google Scholar